INVICTUS JUMPS TO TOP FIVE IN SHARE APPRECIATION AMONG CANADA'S LEADING CANNABIS COMPANIES FOR 2018 Q1
April 04 2018 - 11:52AM
InvestorsHub NewsWire
Vancouver, BC --
April 4, 2018 -- InvestorsHub NewsWire -- INVICTUS MD STRATEGIES
CORP. ("Invictus" or the "Company") (TSXV: GENE; OTC: IVITF; FRA:
8IS1) is pleased to announce, on the heels of kicking
off construction on 40,000 sq. ft. of additional cultivation space
and appointing Rock & Roll Hall of Famer Gene Simmons of KISS
as Chief Evangelist Officer, Invictus ranked fifth overall in share
appreciation among Canada’s Cannabis leaders for the first quarter
of 2018 and was the overall top performer last week, according to
Mackie Research’s The Daily Extract - Weekend Edition - April
1, 2018 (source: Capitol IQ).
“With legislation on track to legalize adult use of cannabis by the
end of summer, Invictus, has a strong foundation and is well
positioned to take a stronghold in this multi-billion dollar
industry,” said Dan Kriznic, Chairman and CEO of Invictus.
Founded in Vancouver, BC, Invictus is a cannabis company that is
dedicated to offering high-quality, regulated cannabis for medical
use and for adult use as Canada marches towards full legalization
during 2018. The Company owns a platform of licensed cannabis
producers located throughout Canada who operate under the Access to
Cannabis for Medical Purposes Regulations (the “ACMPR”). The
Company’s growers are supported by more than 250 acres of
production capacity and have total access to Invictus’ team of
leading horticulturists, biochemists and project managers.
Invictus stands out among very few Canadian cannabis companies that
have declared dividends and is well-positioned to become one of the
leaders in the legal cannabis space – not just in Canada but
globally.
About Invictus
Invictus owns and operates cannabis companies in Canada with the
vision of producing a variety of high quality and low cost cannabis
products and strains to the global market place as regulations
permit. Gene Simmons, music legend and media mogul, conveys the
vision of Invictus as the Chief Evangelist Officer.
Invictus operates two cannabis production sites under the Access to
Cannabis for Medical Purposes Regulations
(“ACMPR”) in Canada and has over 95,000 square
feet of cannabis production capacity at the licensed production
sites. The Company’s wholly owned subsidiary Acreage Pharms
Ltd. (“Acreage Pharms”), located in West-Central
Alberta on 150 acres, has approximately 40,000 square feet of
cannabis ready production with its recently completed Phase 2
expansion. The Company intends on expanding to 120,000 square
feet by the end of 2018 once Phase 3 is complete.
Invictus also owns 50% of AB Laboratories Inc. (“AB
Labs”), a licensed producer under the ACMPR located in
Hamilton, Ontario. AB Labs currently operates in a 16,000 square
foot facility and recently acquired a facility adjacent to the
existing property that will allow for a total of 56,000 square feet
of cultivation space expected to be ready for production by June
2018. During the first quarter of 2018 AB Labs submitted a
secondary license to Health Canada for a nearby property on 100
acres under the name AB Ventures Inc. (“AB
Ventures”). Invictus has committed $5.5 million in cash to
AB Ventures to secure its 33 1/3 percent ownership and allow AB
Ventures to build its first 20,000 square foot facility on the
100-acre property.
Combined, the licensed producers owned by Invictus expect to have
approximately 200,000 square feet of cannabis production capacity
by the end of 2018 and 520,000 square feet of cannabis production
capacity by the end of 2019.
In addition to the ACMPR licenses, the Company has an 82.5%
investment in Future Harvest Development Ltd. a high quality
Fertilizer and Nutrients manufacturer based in Kelowna,
British Columbia that has been in operation for over 20 years under
the brand Plant Life Products and Holland Secret.
For more information, please visit www.invictus-md.com.
On Behalf of the Board,
Dan Kriznic
Chairman & CEO
Larry Heinzlmeir
Vice President, Marketing & Communications
604-537-8676
In the United States
Terry Wills
twills@willscom.com
310-877-1458
Cautionary Note Regarding Forward-Looking Statements: This release
includes certain statements and information that may constitute
forward-looking information within the meaning of applicable
Canadian securities laws or forward-looking statements within the
meaning of the United States Private Securities Litigation Reform
Act of 1995. All statements in this news release, other than
statements of historical facts, including statements regarding
future estimates, plans, objectives, timing, assumptions or
expectations of future performance, including the potential
production capacity of AB Labs, AB Ventures and Acreage Pharms, the
completion of AB Ventures and Acreage Pharms’ production
facilities, the granting of regulatory approval and anticipated
timing of AB Labs reaching full production capacity, the granting
of AB Labs secondary license, the granting of a sales license under
the ACMPR to Acreage Pharms, expected sales of inventory and the
legalization of the recreational use of marijuana in Canada in 2018
are forward-looking statements and contain forward-looking
information. Generally, forward-looking statements and information
can be identified by the use of forward-looking terminology such as
“intends” or “anticipates”, or variations of such words and phrases
or statements that certain actions, events or results “may”,
“could”, “should”, “would” or “occur”. Forward-looking statements
are based on certain material assumptions and analysis made by the
Company and the opinions and estimates of management as of the date
of this press release, AB Labs will be successful in reaching its
potential production capacity on the timeline expected by the
Company, AB Ventures and Acreage Pharms’ production facilities will
be completed as anticipated, regulatory approval will be granted as
anticipated, AB Labs will reach full production capacity on the
timeline anticipated by the Company, AB Labs will be granted its
secondary license on the terms and timeline anticipated by the
Company, no unforeseen construction delays will be experienced,
Acreage Pharms will be granted its sales license under the ACMPR on
the terms and timeline anticipated by the Company, expected sales
of inventory will be met and the legalization of the recreational
use of marijuana in Canada will occur as expected. These
forward-looking statements are subject to known and unknown risks,
uncertainties and other factors that may cause the actual results,
level of activity, performance or achievements of the Company to be
materially different from those expressed or implied by such
forward-looking statements or forward-looking information.
Important factors that may cause actual results to vary, include,
without limitation, AB Labs will not be successful in reaching its
potential production capacity, AB Ventures and Acreage Pharms’
production facilities will not be completed as anticipated,
construction delays, regulatory approval will not be granted as
anticipated and therefore, the anticipated timing of AB Labs
reaching full production capacity will be delayed, AB Labs not be
granted their secondary license, Acreage Pharms will not be
granted its sales license under the ACMPR, licenses or approvals
being granted on terms or timelines that are materially worse than
expected by the Company, expected sales of inventory will not be
met and the legalization of the recreational use of marijuana in
Canada will not occur at all or as expected. Although
management of the Company has attempted to identify important
factors that could cause actual results to differ materially from
those contained in forward-looking statements or forward-looking
information, there may be other factors that cause results not to
be as anticipated, estimated or intended. There can be no assurance
that such statements will prove to be accurate, as actual results
and future events could differ materially from those anticipated in
such statements. Accordingly, readers should not place undue
reliance on forward-looking statements and forward-looking
information. Readers are cautioned that reliance on such
information may not be appropriate for other purposes. The Company
does not undertake to update any forward-looking statement,
forward-looking information or financial out-look that are
incorporated by reference herein, except in accordance with
applicable securities laws. We seek safe harbor.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Invictus MD Strategies (TSXV:GENE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Invictus MD Strategies (TSXV:GENE)
Historical Stock Chart
From Sep 2023 to Sep 2024